The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Gain on marketable securities | 0 |
| Accrued interest settled with common stock | 0 |
| Loss on settlement of convertible debt | 0 |
| Expense for debt issuance costs due to fair value election on convertible notes | 0 |
| Expense for issuance costs due to liability classified warrants | 0 |
| Loss on issuance of convertible notes - fair value option | 0 |
| Accrued interest income | 0 |
| Accounts payable and accrued expenses - related parties | 0 |
| Accrued interest payable | 0 |
| Other assets | 0 |
| Net loss | -11,721,669 |
| Depreciation and amortization | 290,107 |
| Change in fair value of derivative liabilities | -74,406 |
| Amortization of debt discount and finance fees | 62,030 |
| Gain on settlement of debt | -342,650 |
| Stock-based compensation | 932,967 |
| Interest payments on convertible notes accounted for at fair value | -115,339 |
| Change in fair value of convertible notes | -3,351 |
| Prepaid expenses | -121,867 |
| Accounts payable and accrued expenses | 422,994 |
| Accrued interest payable - related parties | -1,785 |
| Change in operating lease asset and liabilities | -2,459 |
| Impairment of right-of-use asset | 109,235 |
| Net cash used in operating activities | -9,481,645 |
| Investment in marketable securities | 0 |
| Proceeds from disposition of marketable securities | 0 |
| Investment in developed technology related to molecule.ai asset acquisition | 3,044,722 |
| Payments made for capitalized software | 12,000 |
| Net cash (used in) provided by investing activities | -3,056,722 |
| Proceeds from note payable-related party | 0 |
| Proceeds from convertible notes payable | 0 |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of placement agent fees of 504,770 | 0 |
| Payment for issuance costs related to liability-classified warrants | 0 |
| Payment of convertible note payable | 0 |
| Repayment of note payable-related party | 190,270 |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 322,501 | 5,409,673 |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 170,000 | 4,080,000 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs of 235,514 | 2,264,485 |
| Payment of other issuance costs for issuance of common stock and equity-classified warrants | 557,659 |
| Proceeds from exercise of pre-funded warrants | 20,151 |
| Payment for finance costs | 74,152 |
| Net cash provided by (used in) financing activities | 10,952,228 |
| Net change in cash and cash equivalents | -1,586,139 |
| Net change in cash and cash equivalents | -1,586,139 |
| Cash and cash equivalents, beginning of period | 1,920,144 |
| Cash and cash equivalents, end of period | 334,005 |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)